A Multicenter Phase I Study of CTLA-4 Blockade with Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation
Matthew S. Davids(Dana-Farber Cancer Institute), Robert J. Soiffer(Dana-Farber Cancer Institute), Asad Bashey, Haesook T. Kim(Dana-Farber Cancer Institute), David Avigan(Beth Israel Deaconess Medical Center), Philippe Armand(Harvard University), Edwin P. Alyea(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Caitlin Costello(University of California San Diego), Rebecca Liguori(Dana-Farber Cancer Institute), Peter A. McSweeney(Colorado Blood Cancer Institute), Jacquelyn Hedlund(New England Cancer Specialists), Jerome Ritz(Dana-Farber Cancer Institute), Edward D. Ball(Sheba Medical Center), Yi‐Bin Chen(Massachusetts General Hospital)
Cited by 17
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k